----item----
version: 1
id: {A1590330-F30B-4513-A06B-47D94406E94D}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/05/15/US quarterly results roundup
parent: {166B4D89-6B6A-4D16-8DA9-761C7F941ECD}
name: US quarterly results roundup
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: a77d470e-e120-4ee4-b0f9-33783da93cdb

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 3

<p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 29

US quarterly results round-up
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1978

<p><pre>Cholestech Revenues Net loss ($ millions) ($ millions) 1995 1994 1995 1994 Year 4.04 3.03 (5.04) (8.91) (ended Mar 31st, 1995; Mar 25th, 1994)</pre><p>In fiscal 1995, Cholestech's US sales increased 75% to $3.2 million, a rise attributed to sales of the company's HDL cholesterol products and the introduction of two glucose products.</p><pre>Molecular Dynamics Revenues Net income (loss) ($ millions) ($ millions) 1994 1993 1994 1993 3 months 9.37 9.72 0.29 1.00 Year 33.86 38.08 (4.70) 3.98 (ended Dec 31st)</pre><p>Molecular Dynamics' 1994 net loss was caused by lower turnover and a $2 million settlement charge related to a class action suit. The company says that sales of its FluorImager fluorescence-detection system increased in the second half of the year. In December, the company introduced three new Vistra Fluorescence reagent kits co-developed with Amersham International, its partner since April 1994. Molecular's next-generation PhosphorImager system is expected to be introduced in the second quarter of 1995.</p><pre>Coherent Revenues Net income ($ millions) ($ millions) 1995 1994 1995 1994 3 months 66.46 55.22 4.39 2.96 6 months 125.04 102.24 7.88 4.39 (ended Apr 1st, 1995; Apr 2nd, 1994)</pre><p>Coherent has enjoyed a 47% order surge in the second quarter compared with a year earlier. In the first fiscal half, orders were up 37%, increasing the company's order backlog by $23 million in the period. Medical segment sales in the first half were up 33% and electro-optical by 15%.</p><pre>Inamed Revenues Net income (loss) ($ millions) ($ millions) 1994 1993 1994 1993 Year 80.39 74.50 2.75 (4.08) (ended Dec 31st)</pre><p>Inamed says it will continue to incur increased legal costs until the global breast implant settlement is finalised. The company has agreed to contribute $25 million to the settlement. Inamed's chairman, Donald McGhan, says the silicone gastric band for the treatment of morbid obesity is in clinical trials in the US.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{72D49F7F-DA69-4EE0-ACAA-8D50362AD510}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 28

US quarterly results roundup
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950515T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950515T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950515T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT052627
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 29

US quarterly results round-up
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

254436
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184235Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

a77d470e-e120-4ee4-b0f9-33783da93cdb
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184235Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
